Oncimmune Limited (Oncimmune) is engaged in providing a variety of innovative pharmaceutical products. The company is principally involved in commercialization of cancer related technologies. It offers patented EarlyCDT technology that is widely applicable in the detection of lung cancer. The company is also involved in the development of novel tests for various solid-tumor cancers including stomach, pancreas, breast, colon, and prostate. It operates in collaboration with Lachesis Seed Capital, Balderton Capital and the University of Nottingham. The company commercializes EarlyCDT-lung tests through its own panel of medical professionals in Canada and the US. Oncimmune is headquartered in Nottingham, the UK.